Technical Analysis for ARNI - Arno Therapeutics

Grade Last Price % Change Price Change
grade B 0.0035 105.88% 0.0018
ARNI closed up 105.88 percent on Thursday, November 14, 2019, on 25 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical ARNI trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
MACD Bullish Centerline Cross Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Gapped Up Strength 0.00%
Fell Below 50 DMA Bearish 105.88%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 105.88%
Narrow Range Bar Range Contraction 105.88%
Wide Bands Range Expansion 105.88%

Older signals for ARNI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Arno Therapeutics, Inc. is an early-stage company focused on developing products for the treatment of cancer and other life threatening diseases. The Company's product development pipeline includes Onapristone, AR-42, and AR-12 and analogs. Onapristone is indicated for endometrial, prostate and breast cancer indications. AR-42 is provided for hematological malignancies and solid tumors indications. AR-12 is offered for solid tumors and hematological malignancies, and various anti-microbial targets. Onapristone is a type 1 anti-progestin hormone blocker that has considerable anti-tumor activity in patients with breast cancer. The Company is engaged in developing and commercializing AR-42, which is an oral cancer therapy in early clinical development. AR-42 is a spectrum deacetylase inhibitor of both histone and non-histone proteins, which has potency and activity in solid tumors and hematological malignancies. AR-12 is an orally available cancer treatment.
Medicine RTT Cancer Clinical Medicine Drugs Diseases Treatment Of Cancer Solid Tumors Chemotherapy Alcohols Breast Cancer Antineoplastic Drugs Cancer Treatment Cancer Therapy Treating Cancer Amines Hematological Malignancies Tumors Of The Hematopoietic And Lymphoid Tissues Estranes Oral Cancer
Is ARNI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 0.09
52 Week Low 0.0005
Average Volume 39,933
200-Day Moving Average 0.0191
50-Day Moving Average 0.0018
20-Day Moving Average 0.0017
10-Day Moving Average 0.002
Average True Range 0.0008
ADX 33.37
+DI 68.0
-DI 9.3333
Chandelier Exit (Long, 3 ATRs ) 0.0017
Chandelier Exit (Short, 3 ATRs ) 0.0034
Upper Bollinger Band 0.0028
Lower Bollinger Band 0.0006
Percent B (%b) 1.32
BandWidth 129.411765
MACD Line 0.0
MACD Signal Line -0.0002
MACD Histogram 0.0002
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0035
Resistance 3 (R3) 0.0035 0.0035 0.0035
Resistance 2 (R2) 0.0035 0.0035 0.0035 0.0035
Resistance 1 (R1) 0.0035 0.0035 0.0035 0.0035 0.0035
Pivot Point 0.0035 0.0035 0.0035 0.0035 0.0035
Support 1 (S1) 0.0035 0.0035 0.0035 0.0035 0.0035
Support 2 (S2) 0.0035 0.0035 0.0035 0.0035
Support 3 (S3) 0.0035 0.0035 0.0035
Support 4 (S4) 0.0035